Helen McBride, PhD brings more than 25 years of experience in life sciences, biotechnology, and investment. She is a Partner at Bold Capital Partners, where she invests at the intersection of technology and life sciences to advance innovative solutions to improve human healthspan, and serves on multiple biotech and medical device boards. Her career includes senior leadership roles at TORL Biotherapeutics, the California Institute of Technology (Caltech), and Amgen, where she led and contributed to multiple therapeutic projects, a handful of which are now commercial products generating over $4B in revenue. Dr. McBride holds a PhD in oncological sciences from the University of Utah and a BS in microbiology from Texas A&M University. An accomplished scientist and strategic leader, she has authored more than 35 peer-reviewed publications and remains active in professional and community leadership, including serving as president of the Los Angeles chapter of the Healthcare Businesswomen’s Association (HBA).